LABCORP HOLDINGS INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LH in the last 30 days.
See all $LH insider activity →Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.
Labcorp acquired MLM Medical Labs, expanding its global clinical trial lab network to four continents. The deal enhances Labcorp's biomarker and specialty testing capabilities, supporting complex multinational trials. Financial terms were not disclosed.
Labcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LH (LABCORP HOLDINGS INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent LH coverage spans mergers & acquisitions, regulation and earnings.
Modest beat may sustain short-term price gain.
The deal enhances Labcorp's international footprint, potentially boosting revenue from multinational trial services.
Potential revenue uplift from offering the first FDA‑cleared single‑biomarker Alzheimer's test.
Analyst upgrade may support short-term upside.
The lack of upside guidance caused a sell‑off, suggesting short‑term downside pressure.
AlphAI scores every news story that mentions LH with an AI model for sentiment and relevance, and aggregates insider trades from LABCORP HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.
3 min readLabcorp acquired MLM Medical Labs, expanding its global clinical trial lab network to four continents. The deal enhances Labcorp's biomarker and specialty testing capabilities, supporting complex multinational trials. Financial terms were not disclosed.
2 min readLabcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.
1 min readUBS maintained a 'Buy' rating for Labcorp Holdings (LH) and raised its price target to $380 from $361. GuruFocus values LH at $277.40, indicating a 10.5% overvaluation. The company has a GF Score of 80/100, showing strong profitability and momentum. Insiders sold $3.27 million in shares over the past three months.
1 min readLabcorp (LH) stock fell 4.3% to $307.43 after its 2026 Investor Day, where it reaffirmed revenue guidance of $14.71B-$14.83B and EPS growth of 8.5%-11.5%. The market expected a guidance raise, and the lack of upside led to profit-taking. Broader market declines also pressured the stock.
2 min readLabcorp (LH) reaffirmed its 2026 guidance and provided a long-term outlook through 2029, targeting 5-8% annual revenue growth and 8.5-11.5% adjusted EPS growth. The company outlined strategic priorities in specialty testing, partnerships, personalized health, and technology at its Investor Day.
5 min readGreat Point Partners sold MLM Medical Labs to Labcorp. MLM, which quadrupled revenue and EBITDA under Great Point, offers clinical lab services globally. Labcorp gains expanded infrastructure. Financial terms were not disclosed.
2 min readLabcorp (NYSE: LH) acquired MLM Medical Labs, expanding its global central laboratory network to four continents. The deal enhances Labcorp's biomarker and specialty testing capabilities, strengthening its position in clinical trial services. Financial terms were not disclosed.
2 min readRoche's Elecsys pTau217 assay and Labcorp's Alzheimer’s test received FDA clearance, enabling broader use in primary care. This shift requires health systems to adapt workflows, EHR systems, and clinician training. The operational challenge includes integrating results into clinical pathways to avoid alert fatigue and ensure actionable outcomes.
2 min readThe FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.
2 min read
